Interaction of multidrug-resistant hypervirulent Klebsiella pneumoniae with components of human innate host defense.

Autor:	DeLeo FR; Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana, USA., Porter AR; Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana, USA., Kobayashi SD; Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana, USA., Freedman B; Laboratory of Bacteriology, Rocky Mountain Laboratories, National Institute of Allergy and Infectious Diseases, National Institutes of Health , Hamilton, Montana, USA., Hao M; Department of Clinical Laboratory Medicine, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Medicine and Health Key Laboratory of Laboratory Medicine , Jinan, China., Jiang J; Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey, USA., Lin Y-T; Division of Infectious Diseases, Department of Medicine, Taipei Veterans General Hospital , Taipei, Taiwan.; Institute of Emergency and Critical Care Medicine, National Yang Ming Chiao Tung University , Taipei, Taiwan., Kreiswirth BN; Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey, USA., Chen L; Center for Discovery and Innovation, Hackensack Meridian Health , Nutley, New Jersey, USA.
Jazyk:	angličtina
Zdroj:	MBio [mBio] 2023 Oct 31; Vol. 14 (5), pp. e0194923. Date of Electronic Publication: 2023 Sep 06.
DOI:	10.1128/mbio.01949-23
Abstrakt:	Importance: Klebsiella pneumoniae strains with a combination of multidrug resistance and hypervirulence genotypes (MDR hvKp) have emerged as a cause of human infections. The ability of these microbes to avoid killing by the innate immune system remains to be tested fully. To that end, we compared the ability of a global collection of hvKp and MDR hvKp clinical isolates to survive in human blood and resist phagocytic killing by human neutrophils. The two MDR hvKp clinical isolates tested (ST11 and ST147) were killed in human blood and by human neutrophils in vitro , whereas phagocytic killing of hvKp clinical isolates (ST23 and ST86) required specific antisera. Although the data were varied and often isolate specific, they are an important first step toward gaining an enhanced understanding of host defense against MDR hvKp. Competing Interests: The authors declare no conflict of interest.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu